The Ministry of Health has published EBOLA DRC - Evolution of the response to the Ebola outbreak in the provinces of North Kivu and Ituri to Friday, May 24, 2019. Excerpt from the Google translation:
EVOLUTION OF THE EBOLA EPIDEMIC IN THE PROVINCES OF NORTH KIVU AND ITURI
Friday, May 24, 2019
The epidemiological situation of the Ebola Virus Disease dated 23 May 2019:
• Since the beginning of the epidemic, the cumulative number of cases is 1,888, of which 1,800 are confirmed and 88 are probable. In total, there were 1,254 deaths (1,166 confirmed and 88 probable) and 492 people cured.
• 343 suspected cases under investigation;
• 11 new confirmed cases, including 3 in Mabalako, 3 in Katwa, 2 in Butembo, 2 in Mandima and 1 in Kalunguta;
• 6 new confirmed deaths, including:
º 5 community deaths, 2 in Mandima, 1 in Butembo, 1 in Katwa and 1 in Kalunguta;
• 1 death at Katwa CTE;
• 2 new healings from the Katwa CTE.
/! \ The data presented in this table are subject to change later, after extensive investigations and after redistribution of cases and deaths in their health areas.
FIGURES OF THE RESPONSE
123,526 vaccinated persons
831 people vaccinated on 23/05/2019.
• Of those vaccinated, 34,048 are high-risk contacts (CHR), 60,522 are contacts of contacts (CC), and 28,956 are first-line providers (PPL).
• Persons vaccinated by health zone: 32,412 in Katwa, 25,048 in Beni, 15,798 in Butembo, 9,883 in Mabalako, 6,033 in Mandima, 4,379 in Kalunguta, 3,070 in Goma, 3,048 in Komanda, 2,569 in Oicha, 2,035 in Masereka, 1,998 in Lubero , 1,980 to Kayna, 1,935 to Vuhovi, 1,817 to Kyondo, 1,657 to Musienene, 1,487 to Bunia, 1,040 to Biena, 1,012 to Mutwanga, 690 to Rutshuru, 557 to Rwampara (Ituri), 527 to Nyankunde, 496 to Mangurujipa, 494 to Alimbongo, 420 to Mambasa, 355 to Tchomia, 342 to Kirotshe, 333 to Lolwa, 250 to Mweso, 245 to Kibirizi, 161 to Nyiragongo, 97 to Watsa (Haut-Uélé) and 13 to Kisangani.
• The only vaccine to be used in this outbreak is the rVSV-ZEBOV vaccine, manufactured by the pharmaceutical group Merck, following approval by the Ethics Committee in its decision of 19 May 2018.
